RSS Feed
Article
FDA Advisory Panels: A Coin Flip
FDA advisory panels in 2010 are voting against new drugs more than any other time since 2007.
10:25AM 09/02/10
Article
Somaxon: Readers Respond (Angrily)
Most, but not all, readers unhappy with Adam Feuerstein's skeptical take on Somaxon and its soon-to-be-launched insomnia drug Silenor.
07:07AM 09/02/10
Article
Orexigen, Takeda Tie Knot on Obesity Drug
Orexigen gets $50 million upfront for North American rights to its experimental obesity drug Contrave
06:50AM 09/02/10
Article
Biotech Calendar: Key Dates for September
Here's a list of September's potentially stock-moving biotech events
07:00AM 09/01/10
Article
Genzyme Sale Inevitable, Buysiders Say
Sooner or later Sanofi-Aventis will cough up more cash and buy Genzyme, predicts a group of healthcare investors.
12:33AM 09/01/10
Article
Dendreon: Medicare Coverage Fears Allayed
Medicare sets a Nov. 17 meeting to discuss Dendreon's Provenge, but the focus will be on which patients should get the prostate cancer vaccine, not whether to cover it at all.
08:10PM 08/31/10
Article
Dendreon Gets Date for Medicare Meeting
Medicare will hold a meeting Nov. 17 to discuss use of Dendreon's prostate cancer vaccine Provenge.
05:05PM 08/31/10
Article
Somaxon: P&G Won't Wake Up Silenor Sales
Somaxon lands a big-name marketing partner for its sleep drug Silenor, but competition from cheap generics remains a challenging impediment.
12:31PM 08/31/10
Article
21 Drugs Facing FDA Approval Decisions
Here is the updated list of drugs facing FDA approval decisions.
08:21AM 08/31/10
Article
ImmunoGen Wounds Are Not Fatal
The approval delay for the breast cancer drug TDM-1 is a clear setback, but the drug works and patient investors will still be rewarded.
01:56PM 08/30/10
Connect with TheStreet